Nucleotide compounds that block the bitter taste of oral compositions
AssigneeLinguagen Corporation
InventorsRichard Alexander McGregor, Stephen Anthony Gravina
Life of this patent
Estimating the term…
Abstract
Nucleotides that block the bitter taste of foods, beverages, pharmaceutically active oral dose preparations, cosmetics and other bitter compounds that come into contact with taste tissue. The nucleotides consist of a purine or pyrimidine group, or derivative thereof, and an ionizable phosphate or other anionic organic molecule.
Claims26
A composition comprising a bitter tastant and a bitterness inhibitor, wherein said bitterness inhibitor is adenosine 3′:5′-cyclic monophosphate and the inhibitor is present at a concentration which inhibits bitterness.
A composition comprising a bitter tastant and a bitterness inhibitor, wherein said bitterness inhibitor is guanosine 2′:3′-cyclic monophosphate and the inhibitor is present at a concentration which inhibits bitterness.
A composition comprising a bitter tastant and a bitterness inhibitor, wherein said bitterness inhibitor is guanosine 3′:5′-cyclic monophosphate and the inhibitor is present at a concentration which inhibits bitterness.
A composition comprising a bitter tastant and a bitterness inhibitor, wherein said bitterness inhibitor is cytidine 5′-monophosphate and the inhibitor is present at a concentration which inhibits bitterness.
A composition comprising a bitter tastant and a bitterness inhibitor, wherein said bitterness inhibitor is guanosine 2′-monophosphate and the inhibitor is present at a concentration which inhibits bitterness.
A composition comprising a bitter tastant and a bitterness inhibitor, wherein said bitterness inhibitor is guanosine 3′-monophosphate and the inhibitor is present at a concentration which inhibits bitterness.
A composition comprising a bitter tastant and a bitterness inhibitor, wherein said bitterness inhibitor is guanosine 5′-monophosphate and the inhibitor is present at a concentration which inhibits bitterness.
A composition comprising a bitter tastant and a bitterness inhibitor, wherein said bitterness inhibitor is uridine 5′-monophosphate and the inhibitor is present at a concentration which inhibits bitterness.
A composition comprising a bitter tastant and a bitterness inhibitor, wherein said bitterness inhibitor is 2′ deoxyadenosine 5′-monophosphate and the inhibitor is present at a concentration which inhibits bitterness.
A composition comprising a bitter tastant and a bitterness inhibitor, wherein said bitterness inhibitor is 2′ deoxycytidine 5′-monophosphate and the inhibitor is present at a concentration which inhibits bitterness.
A composition comprising a bitter tastant and a bitterness inhibitor, wherein said bitterness inhibitor is 2′ deoxyguanosine 5″-monophosphate and the inhibitor is present at a concentration which inhibits bitterness.
A composition comprising a bitter tastant and a bitterness inhibitor, wherein said bitterness inhibitor is 2′ deoxyadenosine 5′-triphosphate and the inhibitor is present at a concentration which inhibits bitterness.
A composition comprising a bitter tastant and a bitterness inhibitor, wherein said bitterness inhibitor is a purine or pyrimidine group, or derivative thereof, and ionizable phosphate or other anionic organic molecule and the inhibitor is present at a concentration which inhibits bitterness.
A method of inhibiting the perception of a bitter taste in a subject comprising administering to the subject an effective amount of a bitterness inhibitor wherein said inhibitor is adenosine 3′:5′-cyclic monophosphate.
A method of inhibiting the perception of a bitter taste in a subject comprising administering to the subject an effective amount of a bitterness inhibitor wherein said inhibitor is guanosine 2′:3′-cyclic monophosphate.
A method of inhibiting the perception of a bitter taste in a subject comprising administering to the subject an effective amount of a bitterness inhibitor wherein said inhibitor is guanosine 3′:5′-cyclic monophosphate.
A method of inhibiting the perception of a bitter taste in a subject comprising administering to the subject an effective amount of a bitterness inhibitor wherein said inhibitor is cytidine 5′-monophosphate and the inhibitor.
A method of inhibiting the perception of a bitter taste in a subject comprising administering to the subject an effective amount of a bitterness inhibitor wherein said inhibitor is guanosine 2′-monophosphate.
A method of inhibiting the perception of a bitter taste in a subject comprising administering to the subject an effective amount of a bitterness inhibitor wherein said inhibitor is guanosine 3′-monophosphate.
A method of inhibiting the perception of a bitter taste in a subject comprising administering to the subject an effective amount of a bitterness inhibitor wherein said inhibitor is guanosine 5′-monophosphate.
A method of inhibiting the perception of a bitter taste in a subject comprising administering to the subject an effective amount of a bitterness inhibitor wherein said inhibitor is uridine 5′-monophosphate.
A method of inhibiting the perception of a bitter taste in a subject comprising administering to the subject an effective amount of a bitterness inhibitor wherein said inhibitor is 2′ deoxyadenosine 5′-monophosphate.
A method of inhibiting the perception of a bitter taste in a subject comprising administering to the subject an effective amount of a bitterness inhibitor wherein said inhibitor is 2′ deoxycytidine 5′-monophosphate.
A method of inhibiting the perception of a bitter taste in a subject comprising administering to the subject an effective amount of a bitterness inhibitor wherein said inhibitor is 2′ deoxyguanosine 5′-monophosphate.
A method of inhibiting the perception of a bitter taste in a subject comprising administering to the subject an effective amount of a bitterness inhibitor wherein said inhibitor is 2′ deoxyadenosine 5′-triphosphate.
A method of inhibiting the perception of a bitter taste in a subject comprising administering to the subject an effective amount of a bitterness inhibitor wherein said inhibitor is a purine or pyrimidine group, or derivative thereof, and ionizable phosphate or other anionic organic molecule.
Dependencies are inferred from the claim text.